Zdrowie i gospodarka · 16/11/2011
FDA Clears Way for Travoprost Ophthalmic Solution Approval
The FDA has determined that Travatan (travoprost ophthalmic solution, 0.004%) was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications (ANDAs) for the medication.
Source: Federal Register — Health and Human ServicesOpen original release →